Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6073-6079

  Garcia Prats, Anthony J ^a   Draper, Heather R ^a   Thee, Stephanie ^a,b   Dooley, Kelly E ^c   McIlleron, Helen M ^d   Seddon, James A ^e   Wiesner, Lubbe ^d   Castel, Sandra ^d   Schaaf, H Simon ^a   Hesseling, Anneke C ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ETHAMBUTOL; ISONIAZID; OFLOXACIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACUTE HEPATITIS A; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PHARMACOKINETIC PARAMETERS; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UNDERWEIGHT; VOLUME OF DISTRIBUTION; VOMITING; BLOOD; INFANT; NEWBORN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; OFLOXACIN; PROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84942900655     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01404-15     Document Type: Article

References (37)

1. World Health Organization. 2014. Global tuberculosis report 2014. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global-report/en/. Accessed 25 February 2015.
2. Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Perez-Velez CM, Pagano M, Becerra MC, Cohen T. 2014. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet 383:1572-1579. http://dx.doi.org/10.1016/S0140-6736 (14) 60195-1.
3. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. 2002. Evaluation of young children in contact with adult multidrugresistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 109:765-771. http://dx.doi.org/10.1542/peds.109.5.765.
4. World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/challenges/mdr/programmatic-guidelines-for-mdrtb/en/index.html. Accessed 12 March 2012.
5. Seddon JA, Hesseling AC, Finlayson H, Fielding K, Cox H, Hughes J, Godfrey-Faussett P, Schaaf HS. 2013. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis 57:1676-1684. http://dx.doi.org/10.1093/cid/cit655.
6. Fenlon CH, Cynamon MH. 1986. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob Agents Chemother 29:386-388. http://dx.doi.org/10.1128/AAC.29.3.386.
7. Tsukamura M, Nakamura E, Yoshii S, Amano H. 1985. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 131:352-356.
8. Lode H, Höffken G, Olschewski P, Sievers B, Kirch A, Borner K, Koeppe P. 1987. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother 31:1338-1342. http://dx.doi.org/10.1128/AAC.31.9.1338.
9. Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, Mac Kenzie WR, Weiner M, McIlleron H, Kirkpatrick CM. 2012. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 56:3857-3863. http://dx.doi.org/10.1128/AAC.00048-12.
10. Stambaugh JJ, Berning SE, Bulpitt AE, Hollender ES, Narita M, Ashkin D, Peloquin CA. 2002. Ofloxacin population pharmacokinetics in patients with tuberculosis. Int J Tuberc Lung Dis 6:503-509.
11. Bethell DB, Day NP, Dung NM, McMullin C, Loan HT, Tam DT, Minh LT, Linh NT, Dung NQ, Vinh H, MacGowan AP, White LO, White NJ. 1996. Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrob Agents Chemother 40:2167-2172.
12. Turnidge J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58(Suppl 2):S29-S36.
13. Thee S, Garcia-Prats AJ, McIlleron HM, Wiesner L, Castel S, Norman J, Draper HR, van der Merwe PL, Hesseling AC, Schaaf HS. 2014. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. Antimicrob Agents Chemother 58:2948-2951. http://dx.doi.org/10.1128/AAC.02755-13.
14. World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2008/9789241547581-eng.pdf.
15. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, de la Iglesia FA. 1979. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 51:177-187. http://dx.doi.org/10.1016/0041-008X (79) 90020-6.
16. Burkhardt JE, Walterspiel JN, Schaad UB. 1997. Quinolone arthropathy in animals versus children. Clin Infect Dis 25:1196-1204. http://dx.doi.org/10.1086/516119.
17. Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, Bagchi P, Balis DA, Blumer JL. 2007. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 26:879-891. http://dx.doi.org/10.1097/INF.0b013e3180cbd382.
18. Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. 2002. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 21:525-529. http://dx.doi.org/10.1097/00006454-200206000-00009.
19. Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. 2013. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax 69:458-464. http://dx.doi.org/10.1136/thoraxjnl-2013-203900.
20. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. 2003. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 47:3117-3122. http://dx.doi.org/10.1128/AAC.47.10.3117-3122.2003.
21. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Pena J, Perez-Guzman C, Quelapio MI, Ponce-de-Leon A, et al. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data metaanalysis of 9, 153 patients. PLoS Med 9:e1001300. http://dx.doi.org/10.1371/journal.pmed.1001300.
22. Padarath A, English R (ed). 2010. South African health review 2011. Health Systems Trust, Durban, South Africa. http://www.hst.org.za/publications/south-african-health-review-2011. Accessed May 15, 2012.
23. Schaaf HS, Hesseling AC, Rautenbach C, Seddon JA. 2014. Trends in childhood drug-resistant tuberculosis in South Africa: a window into the wider epidemic? Int J Tuberc Lung Dis 18:770-773. http://dx.doi.org/10.5588/ijtld.13.0069.
24. Republic of South Africa Department of Health. 2011. Management of drug-resistant tuberculosis. Policy guidelines 2011. National Department of Health, Pretoria, South Africa. http://www.rudasa.org.za/index.php/resources/document-library/category/8-tuberculosis. Accessed 20 April 2012.
25. Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, Cuevas LE, Gale M, Gie RP, Grzemska M, Handelsman E, Hatherill M, Hesseling AC, Jean-Philippe P, Kampmann B, Kabra SK, Lienhardt C, Lighter-Fisher J, Madhi S, Makhene M, Marais BJ, McNeeley DF, Menzies H, Mitchell C, Modi S, Mofenson L, Musoke P, Nachman S, Powell C, Rigaud M, Rouzier V, Starke JR, Swaminathan S, Wingfield C. 2012. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 205(Suppl 2):S199-S208. http://dx.doi.org/10.1093/infdis/jis008.
26. Cole TJ, Freeman JV, Preece MA. 1998. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 17:407-429. http://dx.doi.org/10.1002/(SICI) 1097-0258 (19980228) 17:4<407::AID-SIM742>3.0. CO;2-L.
27. Meredith SA, Smith PJ, Norman J, Wiesner L. 2012. An LC-MS/MS method for the determination of ofloxacin in 20 μl human plasma. J Pharm Biomed Anal 58:177-181. http://dx.doi.org/10.1016/j.jpba.2011.09.030.
28. Department of Health and Human Services, National Institute of Allergy and Infectious Diseases Division of AIDS. 2009. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, version 2.0. NIAID, Bethesda, MD. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult-Pediatric-Adverse-Events.pdf.
29. Du Bois D, Du Bois EF. 1916. Clinical calorimetry: tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863-871.
30. Peters AM, Snelling HL, Glass DM, Bird NJ. 2011. Estimation of lean body mass in children. Br J Anaesth 106:719-723. http://dx.doi.org/10.1093/bja/aer057.
31. Seddon JA, Hesseling AC, Willemse M, Donald PR, Schaaf HS. 2012. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 54:157-166. http://dx.doi.org/10.1093/cid/cir772.
32. Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. 2006. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother 50:407-413. http://dx.doi.org/10.1128/AAC.50.2.407-413.2006.
33. Donald PR, Diacon AH. 2008. The early bactericidal activity of antituberculosis drugs: a literature review. Tuberculosis 88(Suppl 1):S75-S83. http://dx.doi.org/10.1016/S1472-9792 (08) 70038-6.
34. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, Hollm-Delgado M-G, Keshavjee S, DeRiemer K, Centis R, D'Ambrosio L, Lange CG, Bauer M, Menzies D. 2013. Resistance to fluoroquinolones and secondline injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 42:156-168. http://dx.doi.org/10.1183/09031936.00134712.
35. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 51:576-582. http://dx.doi.org/10.1128/AAC.00414-06.
36. Upton C. 1994. Sleep disturbance in children treated with ofloxacin. BMJ 309:1411. http://dx.doi.org/10.1136/bmj.309.6966.1411.
37. Thee S, Garcia-Prats AJ, Draper HR, McIlleron HM, Wiesner L, Castel S, Schaaf HS, Hesseling AC. 2015. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis 60:549-556. http://dx.doi.org/10.1093/cid/ciu868.